About

A de-risked commercial stage pharmaceutical company with a focus on addressing iron deficiency via its lead product Ferric Maltol, marketed in the EU as Feraccru® and approved in the US and will be marketed as Accrufer®.

At a glance

Shield is a de-risked commercial stage, pharmaceutical company with a focus on addressing iron deficiency.

Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.

The Group’s lead product, Ferric Maltol, is approved by the FDA and will be marketed in the US as Accrufer®. Ferric Maltol is also approved by the EMA and Swiss Medic and marketed in the European Union as Feraccru® by our commercial partner, Norgine BV.

CEO & Founder

Carl Sterritt

We were delighted that our lead product, Ferric Maltol was approved by the FDA in July 2019 opening up the largest and most attractive reimbursed pharmaceutical market. Our commercial partner, Norgine BV continues to make good progress in the EU market.

 

What sets us apart

  • Lead product Ferric Maltol

    Ferric Maltol, is approved by the FDA and will be marketed in the US as Accrufer®. Ferric Maltol is also approved by the EMA and Swiss Medic and marketed in the European Union as Feraccru® by our commercial partner, Norgine BV. Ferric Maltol offers a number of important advantages compared to the current standard of care for iron deficiency.

  • Large market opportunities with unmet needs

    The US is the world’s largest and most attractively reimbursed pharmaceutical market. There are between 8 million and 9 million patients in the USA who suffer from iron deficiency anaemia and potentially two to three times this number require treatment for iron deficiency. Ferric Maltol is approved by the FDA and will be marketed in the US as Accrufer®.

    In Europe it is estimated that there are more than 40 million people with iron deficiency, representing another significant commercial opportunity. Ferric Maltol is approved by the EMA and Swiss Medic and marketed in the European Union as Feraccru®.

  • Experienced management team with extensive expertise

    The skilled senior management team and board of directors provide strong leadership for the Company’s future growth.

  • Strong intellectual property protection

    The Group’s assets are supported by a suite of robust intellectual property rights including key patents in major markets. The Group’s lead product, Ferric Maltol has exclusive IP rights until the mid-2030’s.

  • Investment Case - STX Fact Sheet

    Read more about the Group’s strong investment case here